1. 1) Faig J, Haughton M, Taylor RC, D’Agostino RB Jr, Whelen MJ, Porosnicu Rodriguez KA, Bonomi M, Murea M, Porosnicu M. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am. J. Clin. Oncol., 2016, 1 (2016).
2. 2) Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. Clin. J. Am. Soc. Nephrol., 11, 1173–1179 (2016).
3. 3) Cole WC, Wolf W. Preparation and metabolism of a cisplatin/serum protein complex. Chem. Biol. Interact., 30, 223–235 (1980).
4. 4) Hanada K, Ninomiya K, Ogata H. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin. J. Pharm. Pharmacol., 52, 1345–1353 (2000).
5. 5) Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther., 86, 396–402 (2009).